6 fold increase in revs...21 Feb 2021 13:16
First half revenue substantially up!
6 x increase in revenue £1.83... maiden profit
Admin £4.9m now £2.9m - less one offs, acquisition costs.
Increased commercial interest for immunoinsights. Better stratification of patients for oncology, autoimmune disease and infectious diseases. Taken on more staff, 7 new contracts signed with biotechs and Pharma companies for business development pipeline. Manage their blood samples by running over proprietary immunoinsights platform and then report data back. (Comment: this has huge potential customer cost savings for targeting autoimmune responses and clinical trials use, platform contains +8k samples, biggest in world!). Now have over 100 business deal opportunities!
EarlyCDT Lung. Progressing well even in lockdown. Thousands of tests delivered in east anglia nhs. Expect another 2 x nhs deals soon. Overseas EarlyCDT Lung distribution forecasts returning to pre covid levels.
Financials on track, even though pandemic fell into 3 year plan. R&D maintained. Current way of working is delivering.
What can we expect.... more contracts to land but contracts are knowledge intensive and take up to 1 year to land but have smoothing in place with arrivals. £10.8m visible from 20 contracts and 80 remaining deals appproaching commercial engagement phase.
Comment: Future is bright, steady cashflow, niche market, very little competition, world leader, US, UK, European, South America and Asian presence. Rapid growth! Revenues will continue, exponential growth for relatively low/similar cost base which is relatively easy to scale up.
Also loads not covered in the interview! Lol!
https://youtu.be/ai2CvyIJSEY
Trek